These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 5663114)

  • 1. Interferon induction and utilization.
    Hilleman MR
    J Cell Physiol; 1968 Feb; 71(1):43-59. PubMed ID: 5663114
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon and interferon inducers in the treatment of malignancies.
    Levy HB
    Arch Intern Med; 1970 Jul; 126(1):78-83. PubMed ID: 5425518
    [No Abstract]   [Full Text] [Related]  

  • 3. [Interferon system in viral hepatitis].
    Lisker Melman M
    Rev Invest Clin; 1990 Jul; 42 Suppl():92-6. PubMed ID: 19256144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antiviral therapy].
    Schaap GJ
    Ned Tijdschr Geneeskd; 1979 Nov; 123(44):1906-9. PubMed ID: 514379
    [No Abstract]   [Full Text] [Related]  

  • 5. [After effects of interferon].
    Ershov FI; Tazulakhova EB
    Antibiotiki; 1970 Sep; 15(9):832-6. PubMed ID: 5496086
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors influencing the interferon response.
    Ho M
    Arch Intern Med; 1970 Jul; 126(1):135-46. PubMed ID: 5425511
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA.
    McHutchison JG; Nainan OV; Alter MJ; Sedghi-Vaziri A; Detmer J; Collins M; Kolberg J
    Hepatology; 1997 Nov; 26(5):1322-7. PubMed ID: 9362379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update on the use of interferons in clinical practice].
    Lauta VM
    Clin Ter; 1995; 146(6-7):393-448. PubMed ID: 7586995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
    Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C.
    Yoshiji H; Noguchi R; Fukui H
    J Gastroenterol; 2005 Feb; 40(2):215-6. PubMed ID: 15770410
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study].
    Ortiz V; Olaso V; López Viedma B; Córdoba J; Molina JM; Lainez B; Pastor M; Berenguer J
    Gastroenterol Hepatol; 1999 Mar; 22(3):122-6. PubMed ID: 10228321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon therapy in chronic hepatitis C and cellular immunity].
    Nikitin IG; Kuznetsov SL; Mordvinova LN; Uskov IuI; Storozhakov GI; Strochenovskiĭ AB
    Klin Med (Mosk); 1999; 77(6):33-7. PubMed ID: 10459217
    [No Abstract]   [Full Text] [Related]  

  • 14. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.
    Reddy KR; Hoofnagle JH; Tong MJ; Lee WM; Pockros P; Heathcote EJ; Albert D; Joh T
    Hepatology; 1999 Sep; 30(3):787-93. PubMed ID: 10462387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of interferon mediated anti-viral resistance.
    Clarke CJ; Trapani JA; Johnstone RW
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):117-30. PubMed ID: 12476793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intercalation monitoring PCR(IM-PCR), its principle and application: quantitative monitoring of HCV RNA in the course of IFN therapy].
    Ishiguro T; Saitoh J
    Rinsho Byori; 1997 Mar; 45(3):213-7. PubMed ID: 9086823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon--the prospects and problems of its use in therapeutic and oncological practice].
    Poverennyĭ AM
    Med Radiol (Mosk); 1983 Jun; 28(6):67-71. PubMed ID: 6191171
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current treatment of chronic hepatitis B].
    Rodríguez M; Pérez R
    Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():51-7. PubMed ID: 11279894
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.